Novel Therapeutic Targets

Autoimmunity results from a break in self-tolerance involving humoral and/or cell-mediated immune mechanisms. One pathological consequence of a failure in central and/or peripheral tolerance is the generation of autoantibodies and subsequent formation of complement-fixing immune complexes that contribute to tissue damage. Prevailing pharmacological strategies for treating autoimmune diseases involve the use of broad-acting immunosuppressants that with long term use have associated toxicities. The current drive in drug development is towards therapies that target a specific biological pathway or pathogenic cell population. Recent discovery of the BAFF-mediated B-cell survival pathway provides a unique opportunity for developing focused intervention for autoreactive B-cell function.

  • Drug Delivery Systems
  • Membrane Proteins/Antagonists & Inhibitors
  • Tumor Necrosis Factor-alpha/Metabolism

Related Conference of Novel Therapeutic Targets

March 04-05, 2019

10th Molecular Immunology & Immunogenetics Congress

Barcelona, Spain
March 18-19, 2019

11th Global Summit on Immunology and Cell Biology

Sydney, Australia
March 18-19, 2019

13th International Congress on Autoimmunity

Brisbane, Australia
April 15-18, 2019

Annual Immunology Conference 2019

Savannah, USA
June 13-14, 2019 |

10th European Immunology Conference

Berlin, Germany
July 24-25, 2019

11th World Congress and Expo on Immunology

Vancouver, Canada
July 29-30 2019

6th International Conference on Parasitology & Microbiology

Amsterdam, Netherlands
October 21-22, 2019

12th Annual Congress on Immunology & Immunogenetics

Rome, Italy
November 22-23, 2019 |

World Conference on Vaccine and Immunology

Dubai, UAE

Novel Therapeutic Targets Conference Speakers

Recommended Sessions

Related Journals

Are you interested in